Based on our findings, thirteen studies comprising 6352 participants evaluated HRs in AML cases with intermediate-risk cytogenetics without NPM1 mutations (11, 13, 15, 16, 18, 20, 21, 23, 25-29). The gene discussed is NPM1; the disease is acute myeloid leukemia.